CA3029890A1 - Tgf-beta superfamily heteromultimers and uses thereof - Google Patents

Tgf-beta superfamily heteromultimers and uses thereof Download PDF

Info

Publication number
CA3029890A1
CA3029890A1 CA3029890A CA3029890A CA3029890A1 CA 3029890 A1 CA3029890 A1 CA 3029890A1 CA 3029890 A CA3029890 A CA 3029890A CA 3029890 A CA3029890 A CA 3029890A CA 3029890 A1 CA3029890 A1 CA 3029890A1
Authority
CA
Canada
Prior art keywords
polypeptide
seq
heteromultimer
amino acids
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3029890A
Other languages
English (en)
French (fr)
Inventor
Ravindra Kumar
Asya Grinberg
Dianne S. Sako
Roselyne CASTONGUAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of CA3029890A1 publication Critical patent/CA3029890A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3029890A 2016-07-07 2017-07-06 Tgf-beta superfamily heteromultimers and uses thereof Pending CA3029890A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662359614P 2016-07-07 2016-07-07
US62/359,614 2016-07-07
US201662404670P 2016-10-05 2016-10-05
US62/404,670 2016-10-05
PCT/US2017/040849 WO2018009624A1 (en) 2016-07-07 2017-07-06 Tgf-beta superfamily heteromultimers and uses thereof

Publications (1)

Publication Number Publication Date
CA3029890A1 true CA3029890A1 (en) 2018-01-11

Family

ID=60913181

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3029890A Pending CA3029890A1 (en) 2016-07-07 2017-07-06 Tgf-beta superfamily heteromultimers and uses thereof

Country Status (6)

Country Link
US (1) US20200071382A1 (enExample)
EP (1) EP3481860A4 (enExample)
JP (2) JP7159148B2 (enExample)
AU (2) AU2017293778B2 (enExample)
CA (1) CA3029890A1 (enExample)
WO (1) WO2018009624A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3280435B1 (en) 2015-04-06 2021-06-02 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CN113683708A (zh) 2015-04-06 2021-11-23 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
AU2017338916B2 (en) 2016-10-05 2022-03-24 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
CN110678195A (zh) 2016-10-05 2020-01-10 阿塞勒隆制药公司 ALK4:ActRIIB异多聚体及其用途
AU2019262139A1 (en) * 2018-05-03 2020-11-26 Acceleron Pharma Inc. Multispecific binders of TGFβ-superfamily ligands and uses thereof
US20220089683A1 (en) * 2018-06-15 2022-03-24 Acceleron Pharma Inc. Bi-and tri-functional fusion proteins and uses thereof
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
EP4433160A1 (en) 2021-11-17 2024-09-25 Disc Medicine, Inc. Methods for treating anemia of kidney disease
WO2026125668A1 (en) * 2024-12-13 2026-06-18 Institut National de la Santé et de la Recherche Médicale Peptide derived from endoglin for treating bleeding disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2686348B1 (en) 2011-03-17 2015-12-30 Ramot at Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
EP3549952A1 (en) * 2011-04-20 2019-10-09 Acceleron Pharma Inc. Endoglin polypeptides and uses thereof
WO2014055869A1 (en) 2012-10-05 2014-04-10 Acceleron Pharma, Inc. Treatment of cancer with alk1 antagonists
AU2014339898B2 (en) * 2013-10-25 2020-07-23 Acceleron Pharma, Inc. Endoglin peptides to treat fibrotic diseases
AU2014388308A1 (en) * 2014-03-28 2016-10-27 Acceleron Pharma, Inc. Use of activin receptor-like kinase 1 (ALK-1) antagonists in the treatment of cancer
WO2015160940A1 (en) 2014-04-15 2015-10-22 President And Fellows Of Harvard College Bi-specific agents

Also Published As

Publication number Publication date
AU2017293778B2 (en) 2022-03-24
AU2017293778A1 (en) 2019-01-24
JP2019527547A (ja) 2019-10-03
EP3481860A4 (en) 2020-01-22
WO2018009624A1 (en) 2018-01-11
US20200071382A1 (en) 2020-03-05
AU2022201603A1 (en) 2022-03-31
EP3481860A1 (en) 2019-05-15
JP7159148B2 (ja) 2022-10-24
JP2022172479A (ja) 2022-11-16

Similar Documents

Publication Publication Date Title
JP7203807B2 (ja) シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用
JP7037363B2 (ja) Ｔｇｆベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体およびその使用
JP7159148B2 (ja) Ｔｇｆベータスーパーファミリーホモ多量体およびその使用
Lowery et al. The BMP pathway and its inhibitors in the skeleton
JP2019527547A5 (enExample)
Santibañez et al. TGF-β/TGF-β receptor system and its role in physiological and pathological conditions
JP2023033573A (ja) バリアントＡｃｔＲＩＩＢタンパク質およびその使用
EP3929211B1 (en) Alk4:actriib heteromultimers and uses thereof
Kimura et al. Oligodendrocytes upregulate blood-brain barrier function through mechanisms other than the PDGF-BB/PDGFRα pathway in the barrier-tightening effect of oligodendrocyte progenitor cells
JP7097354B2 (ja) Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用
JP2018513147A5 (enExample)
JP2018531281A6 (ja) 組織形成誘導用化合物及びその使用
JP2018531281A (ja) 組織形成誘導用化合物及びその使用
JP2018532767A (ja) 組織形成誘導用化合物及びその使用
Egerman et al. ActRII or BMPR ligands inhibit skeletal myoblast differentiation, and BMPs promote heterotopic ossification in skeletal muscles in mice
Eagleson et al. Distinct domains of the limbic system-associated membrane protein (LAMP) mediate discrete effects on neurite outgrowth
JP2019502674A (ja) 組織形成誘導用化合物及びその使用
Kasten et al. The effect of two point mutations in GDF-5 on ectopic bone formation in a β-tricalciumphosphate scaffold
HK40078293A (en) Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
Khodr Initial molecular steps of bone regeneration: cellular scale modulation
HK40011178A (zh) 变体actriib蛋白及其用途
HK1252958B (en) Single-arm type i and type ii receptor fusion proteins and uses thereof
HK1248734B (en) Alk4:actriib heteromultimers and uses thereof
HK1248733B (en) Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220519

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240926

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260106

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260306